Auron Therapeutics aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and reprogram cancer tissue to a more normal phenotype.
Location: United States, Massachusetts, Wellesley
Employees: 11-50
Total raised: $27M
Founded date: 2018
Investors 4
| Date | Name | Website |
| 17.08.2022 | DCVC | dcvc.com/ |
| - | BrightEdge | brightedge... |
| 05.09.2022 | Arkin Hold... | arkinholdi... |
| - | BrightEdge | acsbrighte... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.02.2025 | Series B | $27M | - |
Mentions in press and media 4
| Date | Title | Description |
| 25.02.2025 | Auron Therapeutics Completes $27M Series B | NEWTON, MA, Auron Therapeutics, a clinical-stage biotechnology, has completed a $27 million Series B financing. >> Click here for more funding data on Auron Therapeutics >> To export Auron Therapeutics funding data to PDF and E... |
| 20.07.2022 | Auron Therapeutics Raises $48M in Series A Financing | Auron Therapeutics, a Newton, Mass.-based biopharmaceutical company focused on developing therapies that target dysregulated differentiation and cellular plasticity for treating cancer, closed its $48 million Series A financing round. The r... |
| - | Auron Therapeutics | “Delivering next-generation cancer therapies targeting cell state” |
| - | Auron Therapeutics Closes $12.75 Million Seed Financing to Develop Differentiation Therapies for Treatment of Cancers | Wellesley, Mass., Jan. 27, 2021 – Auron Therapeutics (“Auron”), a biopharmaceutical company focused on developing differentiation therapies for treating cancer, today announced the completion of its $12.75 million seed financing round. Proc... |